C.Q. Pharmaceutical Holding Co Ltd

C.Q. Pharmaceutical Holding Co Ltd has a market capitalization of CNY 10.42 billion and a price-to-earnings ratio of 26.95, which is relatively high compared to the industry median. The company's price-to-book ratio is 0.9, indicating that the market value is slightly below the book value. The enterprise value to EBITDA ratio is 51.42, suggesting a high valuation relative to earnings before interest, taxes, depreciation, and amortization.

The company's profitability is modest, with a return on equity of 3.35% and a return on assets of 0.58%. These figures are below the industry median for pharmaceutical companies, indicating that the company is not generating strong returns relative to its equity and asset base.

Geographically, the company is heavily concentrated in the Chinese market, with no significant international revenue disclosed. This concentration increases exposure to domestic economic and regulatory risks. The company's revenue is derived from a single business segment, which may limit diversification and increase vulnerability to sector-specific downturns.

The company's growth trajectory is mixed. Revenue for the latest period was CNY 8.24 billion, and while the company has a positive operating cash flow of CNY 754.67 million, it has a negative free cash flow of CNY -191.10 million. This suggests that the company is investing in capital expenditures, which may support future growth. However, the company's capital expenditure of CNY -299.54 million indicates a significant investment in infrastructure or expansion.

The company faces several risk factors, including a high debt-to-equity ratio of 2.14 and a current ratio of 1.22, which suggests moderate liquidity risk. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to fund operations without additional financing.

Recent events include a strong analyst recommendation with a mean score of 1.00, indicating a strong buy consensus. The last actual EPS was CNY 0.22, below the mean estimate of CNY 0.33, suggesting potential earnings shortfalls. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.

C.Q. Pharmaceutical Holding Co Ltd (000950.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals & Medical Research. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with industry standards for firms engaged in drug development and medical research activities. Alongside this classification, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is currently assessed as low, indicating a stable capital structure with minimal immediate threat of share value erosion from new issuances. This low dilution risk suggests that existing shareholders are not facing significant pressure from equity expansion at this time. Conversely, liquidity risk has been flagged as medium. This assessment highlights potential constraints in the ease of trading the company’s shares or accessing immediate cash resources, a factor that investors typically monitor closely in the pharmaceutical sector where R&D cycles can be capital-intensive. The medium liquidity rating serves as a cautionary signal regarding market depth or cash flow flexibility. These updates collectively refine the investment profile of C.Q. Pharmaceutical Holding, moving from an undefined state to one with explicit sectoral and risk parameters. While the low dilution risk offers stability, the medium liquidity risk and clear positioning in the competitive Healthcare sector require investors to weigh operational stability against market trading conditions. No analyst coverage or index membership data is currently available to further contextualize these metrics.